468 related articles for article (PubMed ID: 16523432)
1. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
Qureshi IZ; Abid K; Ambreen F; Qureshi AL
Saudi Med J; 2007 Feb; 28(2):193-6. PubMed ID: 17268695
[TBL] [Abstract][Full Text] [Related]
3. [The effects of ACE inhibitor treatment and ACE gene polymorphism on erythropoiesis in chronic hemodialysis patients].
Hatano M; Yoshida T; Mimuro T; Kimata N; Tsuchiya K; Sanaka T; Nihei H
Nihon Jinzo Gakkai Shi; 2000 Oct; 42(8):632-9. PubMed ID: 11195399
[TBL] [Abstract][Full Text] [Related]
4. The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
Odabas AR; Cetinkaya R; Selcuk Y; Keles S; Bilen H
Panminerva Med; 2003 Mar; 45(1):59-62. PubMed ID: 12682621
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis.
Nakamoto H; Kanno Y; Okada H; Suzuki H
Adv Perit Dial; 2004; 20():111-6. PubMed ID: 15384808
[TBL] [Abstract][Full Text] [Related]
6. Association between erythropoietin requirements and antihypertensive agents.
Yano S; Suzuki K; Iwamoto M; Urushidani Y; Yokogi H; Kusakari M; Aoki A; Sumi M; Kitamura K; Sanematsu H; Gohbara M; Imamura S; Sugimoto T
Nephron Clin Pract; 2008; 109(1):c33-9. PubMed ID: 18506108
[TBL] [Abstract][Full Text] [Related]
7. [Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].
Di Iorio B; Guastaferro P; Gironda A; Marano V; Morrongiello L; Cillo N; Zito B; Nigro F; Frieri A; Rubino R; Bellizzi V
G Ital Nefrol; 2002; 19(5):552-9. PubMed ID: 12439845
[TBL] [Abstract][Full Text] [Related]
8. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
Gallucci MT; Lubrano R; Meloni C; Morosetti M; Manca di Villahermosa S; Scoppi P; Palombo G; Castello MA; Casciani CU
Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
[TBL] [Abstract][Full Text] [Related]
9. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
11. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
12. Management of anemia in erythropoietin-resistant hemodialysis patients.
Dar Santos AE; Shalansky KF; Jastrzebski JP
Ann Pharmacother; 2003 Dec; 37(12):1768-73. PubMed ID: 14632604
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin deficiency and relative resistance cause anaemia in post-renal transplant recipients with normal renal function.
Nampoory MR; Johny KV; al-Hilali N; Seshadri MS; Kanagasabhapathy AS
Nephrol Dial Transplant; 1996 Jan; 11(1):177-81. PubMed ID: 8649630
[TBL] [Abstract][Full Text] [Related]
14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
15. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis.
Fang W; Oreopoulos DG; Bargman JM
Nephrol Dial Transplant; 2008 Nov; 23(11):3704-10. PubMed ID: 18567695
[TBL] [Abstract][Full Text] [Related]
16. Perturbation of autocrine/paracrine loops of burst-forming units of erythroid-derived cells in rHuEPO-hyporesponsive hemodialysis patients.
Nakao K; Wada J; Ota K; Ichikawa H; Akagi S; Okamoto A; Hida K; Nagake Y; Makino H
Am J Kidney Dis; 2003 Mar; 41(3):624-36. PubMed ID: 12612986
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
18. Effects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients.
Navarro JF; Macía ML; Mora-Fernández C; Gallego E; Chahin J; Méndez ML; del Castillo N; Rivero A; García J
Adv Perit Dial; 1997; 13():257-9. PubMed ID: 9360694
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
[TBL] [Abstract][Full Text] [Related]
20. Renin-angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance.
DeLong M; Logan JL; Yong KC; Lien YH
Nephrol Dial Transplant; 2005 Mar; 20(3):585-90. PubMed ID: 15735242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
